Financial Summary for the Fiscal Year Ending March 2026 [Japanese Standards] (Consolidated)

Performance Overview

For the fiscal year ending March 2026, the consolidated results were net sales of ¥1,553,364 million (up 2.3% YoY), operating profit of ¥16,601 million (down 12.3% YoY), ordinary income of ¥16,631 million (down 19.7% YoY), and net income attributable to owners of the parent of ¥17,327 million (down 12.7% YoY). The pharmaceutical wholesale segment benefited from growth in anticancer drugs and specialty medicines, although the segment profit decreased due to higher drug procurement costs. The dispensing pharmacy business was restructured, leading to increased sales and significantly higher profits. The pharmaceuticals manufacturing and sales business saw slight revenue growth but a decline in profit. Other peripheral businesses also saw increases in revenue and profit.

Financial Position and Cash Flows

Total assets were ¥740,781 million (up 2.5% YoY), and net assets were ¥271,560 million (up 5.7% YoY). The equity ratio rose to 36.6%. Operating cash flow was a positive ¥19,240 million, investing cash flow was a positive ¥8,220 million, and financing cash flow was a negative ¥16,346 million. Ending cash and cash equivalents amounted to ¥83,286 million.

Forecast for the Fiscal Year Ending March 2027

The consolidated forecast for the Fiscal Year ending March 2027 anticipates net sales of ¥1,601 billion (up 3.1% YoY), operating profit of ¥14.8 billion (down 10.9% YoY), ordinary income of ¥16.6 billion (down 0.2% YoY), and net income attributable to owners of the parent of ¥12.9 billion (down 25.6% YoY). The company aims to strengthen earnings in the pharmaceutical wholesale segment and expand new businesses early, striving for growth despite a challenging business environment.